

Kofnix[®]

Butamirate Citrate

Description

Kofnix[®] is a preparation of Butamirate Citrate which is a non-opioid central cough suppressant. It acts on the cough center in the medulla oblongata. It is neither chemically nor pharmacologically related to opium alkaloids and is safer than codeine. In addition to its antitussive effect, it also exerts expectorant, moderate bronchodilatory action with anti-inflammatory effects. It decreases the airway resistance and improves blood oxygenation.

Indications

Kofnix[®] is indicated for-

- Dry cough of a different origin
- Cough associated with pertussis
- Cough suppression during pre and post-operative surgical interventions (bronchoscopy)

Dosage and administration

Kofnix[®] SR 50 mg tablet:

Adults: 2 to 3 tablets daily at 8 to 12 hours intervals for 5 to 7 days. Maximum duration is up to 2 months in chronic cases.

Children (above 12 years): 1 to 2 tablets daily. Maximum duration is up to 2 months in chronic cases.

Kofnix[®] Syrup:

Adults: 15 ml (3 teaspoonfuls) 4 times daily

Children (above 12 years): 15 ml (3 teaspoonfuls) 3 times daily

Children (6-12 years): 10 ml (2 teaspoonfuls) 3 times daily

Children (3-below 6 years): 5 ml (1 teaspoonful) 3 times daily

Use in pregnancy and lactation

Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. Due to lack of data on elimination of drug in breast milk, it should not be used in lactation.

Side effects

Butamirate Citrate is well tolerated. The common side effects are skin rash, nausea, vomiting, diarrhea, dizziness & vertigo. They disappear after reduction of the dosage or discontinuation of the drug.

Contraindications

It is contraindicated in patients with a known hypersensitivity to the active ingredient or any of the excipients.

Precautions

Due to inhibition of the cough reflex by Butamirate Citrate, the simultaneous administration of an expectorant may induce the accumulation of mucus in the respiratory tract which increases the risk of bronchospasm and airways infection.

Overdose

Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhea and hypotension. The usual emergency assistance should be taken: activated charcoal, saline laxative and symptomatic treatment should be given.

Pharmaceutical precautions

Keep away from the reach of children.

Kofnix[®] SR tablet: Store in a cool and dry place protected from light.

Kofnix[®] syrup: Store in a cool (below 30°C) and dry place protected from light.

Presentation

Kofnix[®] SR tablet: Each sustained release tablet contains Butamirate Citrate INN 50 mg.

Kofnix[®] syrup: Each 5 ml contains Butamirate Citrate INN 7.5 mg.

Packaging

Kofnix[®] SR tablet: Carton of 30 tablets in blister pack.

Kofnix[®] syrup: Bottle of 100 ml.

® Registered Trade Mark



ACI Limited